Context Therapeutics Reports First Quarter 2026 Operating and Financial Results
Context Therapeutics Inc. reported its Q1 2026 financial results and highlighted progress in its clinical pipeline of T cell engaging bispecific antibodies targeting solid tumors. The company expects interim Phase 1a data for CTIM-76 in June and for CT-95 in September 2026, with Phase 1 initiation for CT-202 anticipated in Q3 2026. Cash reserves of…